Glaxo signs $2.1 bln deal for Genmab's lead drug

LONDON, Dec 19 (Reuters) GlaxoSmithKline Plc has bought global rights to Danish biotech company Genmab's most promising new drug, a treatment for leukemia, in a deal worth up to LONDON, Dec 19 (Reuters) GlaxoSmithKline Plc has bought global rights to Danish biotech company Genmab's most promising new drug, a treatment for leukemia, in a deal worth up to $2.1 billion, the two firms said on Tuesday.

The deal covers HuMax-CD20, an experimental antibody medicine in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma. It is also in Phase II trials for rheumatoid arthritis.

REUTERS CS DB1339 .1 billion, the two firms said on Tuesday.

The deal covers HuMax-CD20, an experimental antibody medicine in late-stage development for CD20 positive B-cell chronic lymphocytic leukemia (B-CLL) and follicular non-Hodgkin's lymphoma. It is also in Phase II trials for rheumatoid arthritis.

REUTERS CS DB1339